PCI patients not short-changed by short eptifibatide infusion

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1613, 2007-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Eptifibatide worthwhile in patients undergoing PCI

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 351, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Clinical outcomes are similar for abciximab and eptifibatide in patients who undergo percutaneous coronary intervention (PCI), but abciximab is associated with greater costs

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 493, 2005-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Clinical outcomes are similar for abciximab and eptifibatide in patients who undergo percutaneous coronary intervention (PCI), but abciximab is associated with greater costs

Inpharma, Vol. 1, Iss. 1518, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

High-dose eptifibatide cost saving in low-risk PCI patients?

Inpharma, Vol. 1, Iss. 1285, 2001-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Eptifibatide has long-term benefits post-PCI

Inpharma, Vol. 1, Iss. 1289, 2001-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite